Immunotherapeutic strategies for malignant glioma.

BACKGROUND Despite advances in surgery, radiation therapy, and chemotherapy, only modest improvement has been achieved in the survival of patients with malignant gliomas. METHODS The authors review the immunologic aspects of gliomas, potential targets for therapy, and issues surrounding current immunotherapeutic strategies directed against malignant gliomas. RESULTS The blood-brain barrier and the purported immunological privilege of the brain are not necessarily insurmountable obstacles to effective immunotherapy for brain tumors. Preclinical studies suggest a number of potential therapeutic avenues. Translational studies offer the prospect of providing substantial new information about immunological trafficking in the nervous system and suggesting the most fruitful approaches to immunotherapy for malignant gliomas. CONCLUSIONS More effective adjuvant treatments for malignant gliomas are needed. The applicability of immunological approaches in the treatment of these tumors warrants continued study.

[1]  M. Ciesielski,et al.  Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells , 1998, Oncogene.

[2]  K. Black,et al.  Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. , 2001, Cancer research.

[3]  D. Mercola,et al.  Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Davis,et al.  Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. , 1999, Cancer research.

[5]  J. Becker,et al.  Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.

[6]  G. Giuliani,et al.  Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  W. Markesbery,et al.  Relationship of lymphocyte invasion and survival of brain tumor patients , 1978, Annals of neurology.

[8]  L. Zardi,et al.  Tenascin isoforms: possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. , 1994, Perspectives on developmental neurobiology.

[9]  Erwin G. Van Meir,et al.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? , 1997, The Journal of clinical investigation.

[10]  R O Weller,et al.  Pathways of Fluid Drainage from the Brain ‐ Morphological Aspects and Immunological Significance in Rat and Man , 1992, Brain pathology.

[11]  R. Coleman,et al.  Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Waksal.  Role of an Anti-epidermal Growth Factor Receptor in Treating Cancer , 2004, Cancer and Metastasis Reviews.

[13]  C. Barker,et al.  Immunologically privileged sites. , 1977, Advances in immunology.

[14]  A. Mintz,et al.  IL-13Rα2 is a Glioma-Restricted Receptor for Interleukin-13 , 2002 .

[15]  W. Roa,et al.  Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation , 2002, Acta Neuropathologica.

[16]  J. Koziol,et al.  Interleukin-2 gene therapy in a patient with glioblastoma. , 1995, Gene therapy.

[17]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[18]  T. Ohno,et al.  Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells , 2001, Cancer Immunology, Immunotherapy.

[19]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[20]  S. Sankhla,et al.  Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors , 1996, Journal of Neuro-Oncology.

[21]  P. Humphrey,et al.  Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. , 1991, Biochemical and biophysical research communications.

[22]  R. Merchant,et al.  Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α. Results of a phase I clinical trial , 2004, Journal of Neuro-Oncology.

[23]  D. O’Rourke,et al.  Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Westphal,et al.  Treatment of malignant glioma: a problem beyond the margins of resection , 2001, Journal of Cancer Research and Clinical Oncology.

[25]  R. Plunkett,et al.  The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995. , 2000, Journal of neurosurgery.

[26]  W. Hickey,et al.  Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. , 1998, Journal of immunology.

[27]  F. P. Holladay,et al.  Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with Grade III/IV astrocytoma , 1996, Journal of Neuro-Oncology.

[28]  G. Viale,et al.  Tenascin distribution in human brain tumours , 2005, Acta Neurochirurgica.

[29]  M. Ciesielski,et al.  Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function , 2000, Oncogene.

[30]  R. Coleman,et al.  Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Roszman,et al.  Immune defects observed in patients with primary malignant brain tumors , 1999, Journal of Neuroimmunology.

[32]  K. Jaeckle,et al.  Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Netsky,et al.  DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS , 1972, The Journal of experimental medicine.

[34]  Tejpal Gupta,et al.  Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. , 2002, The Lancet. Oncology.

[35]  R. McLendon,et al.  Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[36]  K. Frei,et al.  T cell suppressor factor from human glioblastoma cells is a 12.5‐kd protein closely related to transforming growth factor‐beta. , 1987, The EMBO journal.

[37]  J. Krauss,et al.  Systemic T cell adoptive immunotherapy of malignant gliomas. , 1998, Journal of neurosurgery.

[38]  J. Connor,et al.  Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  A. Wong,et al.  A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. , 1997, Cancer research.

[40]  M. Ciesielski,et al.  Deletion and tandem duplication of exons 2–7 in the epidermal growth factor receptor gene of a human malignant glioma , 2000, Oncogene.

[41]  A. Das,et al.  Expression of survivin in primary glioblastomas , 2002, Journal of Cancer Research and Clinical Oncology.

[42]  R. Merchant,et al.  Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis , 2001, Cancer Immunology and Immunotherapy.

[43]  M. Varia,et al.  Pilot Study of Local Autologous Tumor Infiltrating Lymphocytes for the Treatment of Recurrent Malignant Gliomas , 2004, Journal of Neuro-Oncology.

[44]  D. Bigner,et al.  Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. , 1977, Journal of neurosurgery.

[45]  D. Bigner,et al.  Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system , 2002, Cancer Immunology, Immunotherapy.

[46]  S. Hoffman,et al.  Improving Protective Immunity Induced by DNA-Based Immunization: Priming with Antigen and GM-CSF-Encoding Plasmid DNA and Boosting with Antigen-Expressing Recombinant Poxvirus1 2 , 2000, The Journal of Immunology.

[47]  C. Patlak,et al.  Albumin outflow into deep cervical lymph from different regions of rabbit brain. , 1991, The American journal of physiology.

[48]  T. Kokunai.  [Anti-TA226 human monoclonal antibody (ACA-11) against glioma]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[49]  W. Hall,et al.  Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. , 1999, Journal of neurosurgery.

[50]  I. Herman,et al.  Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen. , 2001, The American journal of pathology.

[51]  T. Roszman,et al.  Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. , 1984, Journal of immunology.

[52]  M. Shigemori,et al.  Expression of the tumor‐rejection antigen SART1 in brain tumors , 1999, International journal of cancer.

[53]  T. Mikkelsen,et al.  Increasing incidence of primary malignant brain tumors: influence of diagnostic methods. , 1992, Journal of the National Cancer Institute.

[54]  S. Jacobs,et al.  Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. , 1986, Cancer research.

[55]  T. Roszman,et al.  Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor , 1992, Journal of Neuro-Oncology.

[56]  J. Elliott,et al.  Gene Gun Transfection of Human Glioma and Melanoma Cell Lines with Genes Encoding Human IL-12 and GM-CSF , 2000, Journal of Neuro-Oncology.

[57]  W. Hall,et al.  Immunization with Dendritic Cells Pulsed with Tumor Extract Increases Survival of Mice Bearing Intracranial Gliomas , 2004, Journal of Neuro-Oncology.

[58]  T. Cloughesy,et al.  Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. , 1999, Journal of neurosurgery.

[59]  R. Puri,et al.  Interleukin‐13 receptor as a unique target for anti‐glioblastoma therapy , 2001, International journal of cancer.

[60]  E. Jeffes,et al.  Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) Lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA , 1993, Journal of Neuro-Oncology.

[61]  Rolf Larsson,et al.  A New Antibody Recognizing the vIII Mutation of Human Epidermal Growth Factor Receptor , 2002, Tumor Biology.

[62]  P. Caliceti,et al.  Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. , 2001, Cancer biotherapy & radiopharmaceuticals.

[63]  H. Rammensee,et al.  Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. , 2000, Cancer research.

[64]  J. Biegel,et al.  Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.

[65]  K. Itoh,et al.  Expression of the SART1 tumor rejection antigen in renal cell carcinoma , 2000, Urological Research.

[66]  R. Merchant,et al.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes , 1990, Journal of Neuro-Oncology.

[67]  M. Fishman,et al.  Immunotherapy of metastatic renal cell cancer. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[68]  A. Söling,et al.  Dendritic Cell Therapy of Primary Brain Tumors , 2001, Molecular medicine.

[69]  B. Badie,et al.  Expression of Fas ligand by microglia: possible role in glioma immune evasion , 2001, Journal of Neuroimmunology.

[70]  W. Linehan,et al.  Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. , 1999, The Journal of urology.

[71]  K. Black,et al.  Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Warren Rp,et al.  Augmentation of natural killer cell activity by ImuVert: a biological response modifier derived from Serratia marcescens. , 1989 .

[73]  H. Kung,et al.  A complete description of the EGF-receptor exon structure: implication in oncogenic activation and domain evolution. , 1993, Oncogene.

[74]  D. Bigner,et al.  Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. , 1993, Cancer research.

[75]  W. Paulus,et al.  Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. , 1995, The American journal of pathology.

[76]  Yamashita,et al.  Cervical lymph nodes play the role of regional lymph nodes in brain tumour immunity in rats , 1996, Neuropathology and applied neurobiology.

[77]  D. Bigner,et al.  EGF mutant receptor vIII as a molecular target in cancer therapy. , 2001, Endocrine-related cancer.

[78]  E. Oldfield,et al.  Intratumoral LAK cell and interleukin-2 therapy of human gliomas. , 1989, Journal of neurosurgery.

[79]  E. Cohen,et al.  Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. , 1997, Neurosurgery.

[80]  R. McLendon,et al.  Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.

[81]  E. Oldfield,et al.  AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits , 2001, Gene Therapy.

[82]  M. Hamou,et al.  Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. , 1988, Cancer research.

[83]  O. Rott,et al.  Microglial cells qualify as the stimulators of unprimed CD4+ and CD8+ T lymphocytes in the central nervous system , 1994, Clinical and experimental immunology.

[84]  P. Knopf,et al.  Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation 1 This work was supported by National Institute of Health Grant (RO1 NS33070-03) and The Brain Tumor Society. 1 , 1999, Journal of Neuroimmunology.

[85]  G. Dranoff,et al.  Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. , 1997, Cancer gene therapy.

[86]  T. Roszman,et al.  T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. , 1997, Journal of immunology.

[87]  E. Kirches,et al.  Preliminary Results of Active Specific Immunization with Modified Tumor Cell Vaccine in Glioblastoma Multiforme , 2001, Journal of Neuro-Oncology.

[88]  E. Oldfield,et al.  Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. , 1988, Journal of neurosurgery.

[89]  A. Friedman,et al.  Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  P. Linsley,et al.  IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. , 1993, Journal of immunology.

[91]  T. Roszman,et al.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. , 1990, The Journal of clinical investigation.

[92]  J. Verweij,et al.  Immunotherapy of metastatic renal cell cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  Y. Iwadate,et al.  Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors. , 2001, Cancer research.

[94]  C. Sturiale,et al.  Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. , 1995, Cancer research.

[95]  N. Takai,et al.  Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. , 1988, Cancer research.

[96]  M. Shigemori,et al.  Expression of the SART3 Tumor-Rejection Antigen in Brain Tumors and Induction of Cytotoxic T Lymphocytes by Its Peptides , 2000, Journal of immunotherapy.

[97]  G Milano,et al.  Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[98]  E. Oldfield,et al.  Site-specific immune response to implanted gliomas. , 2001, Journal of neurosurgery.

[99]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[100]  P. Walker,et al.  Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. , 1999, International immunology.

[101]  A. Scott,et al.  Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. , 2001, Cancer research.

[102]  D. Bigner,et al.  Prevention of glioma induction in rats by simultaneous intracerebral inoculation of avian sarcoma virus plus bacillus Calmette-Guerin cell-wall preparation. , 1983, Surgical neurology.

[103]  N. Christensen,et al.  IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. , 2002, Neoplasia.

[104]  J. M. Yoffey,et al.  Lymphatics, lymph and the lymphomyeloid complex , 1970 .

[105]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[106]  P. Knopf,et al.  Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid , 1989, Journal of Neuroimmunology.

[107]  H. Fathallah-Shaykh,et al.  Priming in the brain, an immunologically privileged organ, elicits anti‐tumor immunity , 1998, International journal of cancer.

[108]  M. Blaszczyk-Thurin,et al.  A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. , 2002, Anticancer research.

[109]  須川 典亮.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas , 1992 .

[110]  H. Yamana,et al.  Identification of a SART‐1‐derived peptide capable of inducing HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes , 1999, International journal of cancer.

[111]  P. Knopf,et al.  Drainage of Brain Extracellular Fluid into Blood and Deep Cervical Lymph and its Immunological Significance , 1992, Brain pathology.

[112]  P. Wingo,et al.  Cancer statistics, 1995 , 1995, CA: a cancer journal for clinicians.

[113]  H. Hochster,et al.  Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma , 1995, Cancer.